An 11-year-old Texas girl will have a much happier holiday season after an inoperable brain tumor diagnosed earlier this year spontaneously disappeared. (Huffington Post)
A test for cervical cancer using methylation signatures was 100% accurate in a study involving 15,000 women, outperforming both Pap and DNA testing. (IFL Science)
Social media, specifically Facebook, proved to be an effective way to reach people with messages about screening for colon cancer. (University of Colorado at Aurora)
Chemotherapy for most types of solid tumors increased the risk of myelodysplastic syndrome and acute myeloid leukemia. (National Cancer Institute, JAMA Oncology)
Pfizer and Astellas announced that the phase III ARCHES trial met the primary endpoint of improving radiographic progression-free survival in metastatic hormone-sensitive prostate cancer with the addition of enzalutamide (Xtandi) to androgen deprivation therapy.
Seeking to promote “greater predictability and efficiency in oncology drug development,” the FDA announced updated guidance on the selection and definition of endpoints for clinical trials in oncology.
The FDA also granted accelerated approval of pembrolizumab (Keytruda) for the treatment of recurrent locally advanced or metastatic Merkel cell carcinoma.
A new report provides a state-by-state review of the status of palliative care — including resources, access, and delivery of care. (John A Hartford Foundation)
Patients who exercised regularly before and after a cancer diagnosis had significantly better survival. (Roswell Park Comprehensive Cancer Center)
The pharmaceutical industry has turned to artificial intelligence to improve the efficiency and success rate for discovering and producing effective new drugs. (Frost & Sullivan)
The widely used Gleason scoring system for prostate cancer may underestimate mortality risk in black men. (Dana-Farber Cancer Institute, JAMA)